The effect of Elaegnus Angustifolia and Zingiber extract in pain and disability of patient with osteoarthitis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138812121828N3

Enrollment

Registered

2010-04-24

Start date

2010-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis. M15-M19

Interventions

Intervention 1: placebo. Intervention 2: Extract of Elaegnus Angustifolia and Zingiber (200 mg, 2 times per day for 2 monthes).

Placebo

Treatment - Drugs

placebo

Extract of Elaegnus Angustifolia and Zingiber (200 mg, 2 times per day for 2 monthes)

Eligibility

Sex/Gender

All

Age

50 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Osteoarthritis, 2-Age between 50-60 years old, 3-moderate to sever pain, 4- agreement to participition. Exclusion criteria: 1-other types of osteoarticular diseases, 2-uncontrolled hypertension, 3- heart failure(class 3 or 4), 4-chronic renal failure, 5- liver dysfunction, 6-peptic ulcers, 7-history of bronchospasm, 8- history of myocardial infarction or cerebrovascular accidents in last 12 months, 9- increased ES.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: 2 months. Method of measurement: visual analogue scale, patient and physician global assessment the patient and drug usage for pain control in last week.	—

Secondary

Measure	Time frame
Complications. Timepoint: 2 month. Method of measurement: questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Maryam Mobini

Mazandaran university of medical sciences

mmobini50@yahoo.com+98 15 1226 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026